{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:09:47Z","timestamp":1756382987770,"version":"3.37.3"},"reference-count":47,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2020,9,14]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Although the adjuvant therapy of bisphosphonates in prostate cancer is effective in\nimproving bone mineral density, it is still uncertain whether bisphosphonates could decrease the risk of Skeletal-\nRelated Event (SRE) in patients with prostate cancer. We reviewed and analyzed the effect of different types of\nbisphosphonates on the risk of SRE, defined as pathological fracture, spinal cord compression, radiation therapy\nto the bone, surgery to bone, hypercalcemia, bone pain, or death as a result of prostate cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A systemic literature search was conducted on PubMed and related bibliographies. The emphasis\nduring data extraction was laid on the Hazard Ratio (HR) and the corresponding 95% Confidence Interval (CI)\nfrom every eligible Randomized Controlled Trial (RCT). HR was pooled with the fixed effects model, and\npreplanned subgroup analyses were performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> 5 RCTs (n = 4651) were included and analyzed finally after screening 51 articles. The meta-analysis of\nall participants showed no significant decrease in the risk of SRE when adding bisphosphonates to control group\n(HR = 0.968, 95% CI = 0.874 - 1.072, p = 0.536) with low heterogeneity (I2 = 0.0% (d.f. = 4) p = 0.679). There\nwas no significant improvement on SRE neither in the subgroups with Metastases (M1) or Castration-Sensitive\nProstate Cancer (CSPC) (respectively HR = 0.968, 95% CI = 0.874 - 1.072, p = 0.536, I2 = 0.0% (d.f. = 4)\np = 0.679; HR = 0.954, 95% CI = 0.837 - 1.088, p = 0.484, I2 = 0.0% (d.f. = 3) p = 0.534).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Our study demonstrated that bisphosphonates could not statistically significantly reduce the risk of\nSRE in patients with prostate cancer, neither in the subgroups with M1 or CSPC.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520620666200521114815","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T15:38:44Z","timestamp":1590075524000},"page":"1604-1612","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Systematic Review and Meta-Analysis about the Effect of Bisphosphonates on the Risk of Skeletal-Related Event in Men with Prostate Cancer"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7271-6102","authenticated-orcid":true,"given":"Congcong","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Wenzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianghua","family":"Chen","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"author":"Ferlay,J.","key":"ref=1","unstructured":"Ferlay,J.; Colombet,M.; Soerjomataram, I. Estimating the global cancer incidence and mortality in. 2018: GLOBOCAN sources and methods. Int, J. Cancer. 2019,144(8),1941-1953. PMID: 30350310"},{"journal-title":"","author":"","key":"ref=2","unstructured":"Canadian Cancer Society. Prostate cancer statistics. Available at: http:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/prostate\/statistics\/?region=sk 2017"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2017.04.024","volume":"401","author":"Chen,W.","year":"2017","unstructured":"Chen,W.; Zheng,R.; Zhang,S.; Zeng,H.; Xia,C.; Zuo,T.; Yang,Z.; Zou,X.; He, J. Cancer incidence and mortality in China. 2013. Cancer Lett. 2017,401,63-71. http:\/\/dx.doi.org\/10.1016\/j.canlet.2017.04.024 PMID: 28476483","journal-title":"Cancer Lett"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"R305","DOI":"10.1677\/ERC-10-0187","volume":"17(4)","author":"Sharifi,N.","year":"2010","unstructured":"Sharifi,N.; Gulley, J.L.; Dahut, W.L. An update on androgen dep-rivation therapy for prostate cancer. Endocr. Relat. Cancer. 2010,17(4),R305-R315. http:\/\/dx.doi.org\/10.1677\/ERC-10-0187 PMID: 20861285","journal-title":"Endocr.Relat.Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115(11)","author":"Taylor, L.G.","year":"2009","unstructured":"Taylor, L.G.; Canfield, S.E.; Du, X.L. Review of major adverse effects of androgen-deprivation therapy in men with prostate can-cer. Cancer. 2009,115(11),2388-2399. http:\/\/dx.doi.org\/10.1002\/cncr.24283 PMID: 19399748","journal-title":"Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1464-410X.2006.06416.x","volume":"98(5)","author":"Barry, M.J.","year":"2006","unstructured":"Barry, M.J.; Delorenzo, M.A.; Walker-Corkery, E.S.; Lucas, F.L.; Wennberg, D.C. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006,98(5),973-978. http:\/\/dx.doi.org\/10.1111\/j.1464-410X.2006.06416.x PMID: 16879443","journal-title":"BJU Int"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1002\/1097-","volume":"72(12) (Suppl.)","author":"Denis,L.","year":"1993","unstructured":"Denis,L.; Murphy, G.P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer. 1993,72(12) (Suppl.),3888-3895. http:\/\/dx.doi.org\/10.1002\/1097-","journal-title":"Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367(13)","author":"Scher, H.I.","year":"2012","unstructured":"Scher, H.I.; Fizazi,K.; Saad,F.; Taplin, M.E.; Sternberg, C.N.; Miller,K.; de Wit,R.; Mulders,P.; Chi, K.N.; Shore, N.D.; Arm-strong, A.J.; Flaig, T.W.; Fl\u00e9chon,A.; Mainwaring,P.; Fleming,M.; Hainsworth, J.D.; Hirmand,M.; Selby,B.; Seely,L.; de Bono, J.S. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy, N. Engl, J. Med. 2012,367(13),1187-1197. http:\/\/dx.doi.org\/10.1056\/NEJMoa1207506 PMID: 22894553","journal-title":"N.Engl, J.Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351(15)","author":"Tannock, I.F.","year":"2004","unstructured":"Tannock, I.F.; de Wit,R.; Berry, W.R.; Horti,J.; Pluzanska,A.; Chi, K.N.; Oudard,S.; Th\u00e9odore,C.; James, N.D.; Turesson,I.; Rosenthal, M.A.; Eisenberger, M.A. TAX 327 Investigators. Do-cetaxel plus prednisone or mitoxantrone plus prednisone for ad-vanced prostate cancer, N. Engl, J. Med. 2004,351(15),1502-1512. http:\/\/dx.doi.org\/10.1056\/NEJMoa040720 PMID: 15470213","journal-title":"N.Engl, J.Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351(15)","author":"Petrylak, D.P.","year":"2004","unstructured":"Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.; Lara, P.N. Jr; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Berry,D.; Moinpour,C.; Kohli,M.; Benson, M.C.; Small, E.J.; Raghavan,D.; Crawford, E.D. Do-cetaxel and estramustine compared with mitoxantrone and predni-sone for advanced refractory prostate cancer, N. Engl, J. Med. 2004,351(15),1513-1520. http:\/\/dx.doi.org\/10.1056\/NEJMoa041318 PMID: 15470214","journal-title":", N.Engl, J.Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352(2)","author":"Shahinian, V.B.","year":"2005","unstructured":"Shahinian, V.B.; Kuo, Y.F.; Freeman, J.L.; Goodwin, J.S. Risk of fracture after androgen deprivation for prostate cancer, N. Engl, J. Med. 2005,352(2),154-164. http:\/\/dx.doi.org\/10.1056\/NEJMoa041943 PMID: 15647578","journal-title":"Engl, J.Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0022-5347(05) 64985-3","volume":"167(6)","author":"Berruti,A.","year":"2002","unstructured":"Berruti,A.; Dogliotti,L.; Terrone,C.; Cerutti,S.; Isaia,G.; Ta-rabuzzi,R.; Reimondo,G.; Mari,M.; Ardissone,P.; De Luca,S.; Fasolis,G.; Fontana,D.; Rossetti, S.R.; Angeli, A. Gr uppo Onco Urologico Piemontese (G.O.U.P.),Rete Oncologica Piemontese. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy, J. Urol. 2002,167(6),2361-2367. http:\/\/dx.doi.org\/10.1016\/S0022-5347(05) 64985-3 PMID: 11992038","journal-title":"J.Urol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cncr.20388","volume":"101(3)","author":"Krupski, T.L.","year":"2004","unstructured":"Krupski, T.L.; Smith, M.R.; Lee, W.C.; Pashos, C.L.; Brandman,J.; Wang,Q.; Botteman,M.; Litwin, M.S. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004,101(3),541-549. http:\/\/dx.doi.org\/10.1002\/cncr.20388 PMID: 15274067","journal-title":"Cancer"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","volume":"21(23)","author":"Small, E.J.","year":"2003","unstructured":"Small, E.J.; Smith, M.R.; Seaman, J.J.; Petrone,S.; Kowalski, M.O. Combined analysis of two mu lticenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer, J. Clin. Oncol. 2003,21(23),4277-4284. http:\/\/dx.doi.org\/10.1200\/JCO.2003.05.147 PMID: 14581438","journal-title":"Clin.Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/1097-","volume":"88(12) (Suppl.)","author":"Rogers, M.J.","year":"2000","unstructured":"Rogers, M.J.; Gordon,S.; Benford, H.L.; Coxon, F.P.; Luckman, S.P.; Monkkonen,J.; Frith, J.C. Cellular and molecular mecha-nisms of action of bisphosphonates. Cancer. 2000,88(12) (Suppl.),2961-2978. http:\/\/dx.doi.org\/10.1002\/1097-","journal-title":"Cancer"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","volume":"16(12)","author":"Body, J.J.","year":"1998","unstructured":"Body, J.J.; Bartl,R.; Burckhardt,P.; Delmas, P.D.; Diel, I.J.; Fleisch,H.; Kanis, J.A.; Kyle, R.A.; Mundy, G.R.; Paterson, A.H.; Rubens, R.D. International Bone and Cancer Study Group. Current use of bisphosphonates in oncology, J. Clin. Oncol. 1998,16(12),3890-3899. http:\/\/dx.doi.org\/10.1200\/JCO.1998.16.12.3890 PMID: 9850035","journal-title":"J.Clin.Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.eururo.2004.04.022","volume":"46(3)","author":"Montague,R.","year":"2004","unstructured":"Montague,R.; Hart, C.A.; George, N.J.; Ramani, V.A.; Brown, M.D.; Clarke, N.W. Differential inhibition of invasion and prolif-eration by bisphosphonates: Anti-metastatic potential of Zoledronic acid in prostate cancer. Eur. Urol. 2004,46(3),389-401. http:\/\/dx.doi.org\/10.1016\/j.eururo.2004.04.022 PMID: 15306113","journal-title":"Eur.Urol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(09) 70201-3","volume":"10(9)","author":"Dearnaley, D.P.","year":"2009","unstructured":"Dearnaley, D.P.; Mason, M.D.; Parmar, M.K.; Sanders,K.; Sydes, M.R. Adjuvant therapy with oral sodium clodronate in locally ad-vanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009,10(9),872-876. http:\/\/dx.doi.org\/10.1016\/S1470-2045(09) 70201-3 PMID: 19674936","journal-title":"Lancet Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"e1243","DOI":"10.1016\/j.clgc.2018.07.016","volume":"16(6)","author":"Wu,C.","year":"2018","unstructured":"Wu,C.; Chen,W.; Huang,X.; Lin,R.; Wu,J.; Zhang, X. Effect of diphosphonates on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Clin. Genitourin. Cancer. 2018,16(6),e1243-e1250. http:\/\/dx.doi.org\/10.1016\/j.clgc.2018.07.016 PMID: 30146230","journal-title":"Clin.Genitourin.Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","volume":"22(1)","author":"Kamba,T.","year":"2017","unstructured":"Kamba,T.; Kamoto,T.; Maruo,S.; Kikuchi,T.; Shimizu,Y.; Namiki,S.; Fujimoto,K.; Kawanishi,H.; Sato,F.; Narita,S.; Satoh,T.; Saito,H.; Sugimoto,M.; Teishima,J.; Masumori,N.; Egawa,S.; Sakai,H.; Okada,Y.; Terachi,T.; Ogawa, O. ZAPCA Study Group. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: Re-sults of the ZAPCA trial. Int, J. Clin. Oncol. 2017,22(1),166-173. http:\/\/dx.doi.org\/10.1007\/s10147-016-1037-2 PMID: 27614621","journal-title":"Int, J.Clin.Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2015.5570","volume":"2(4)","author":"James, N.D.","year":"2016","unstructured":"James, N.D.; Pirrie, S.J.; Pope, A.M.; Barton,D.; Andronis,L.; Goranitis,I.; Collins,S.; Daunton,A.; McLaren,D.; O\u2019Sullivan,J.; Parker,C.; Porfiri,E.; Staffurth,J.; Stanley,A.; Wylie,J.; Beesley,S.; Birtle,A.; Brown,J.; Chakraborti,P.; Hussain,S.; Russell,M.; Billingham, L.J. Clinical outcomes and survival following treat-ment of metastatic castrate-refractory prostate cancer With do-cetaxel alone or with strontium-89, zoledronic acid, or both: The TRAPEZE randomized clinical trial,J. AMA Oncol. 2016,2(4),493-499. http:\/\/dx.doi.org\/10.1001\/jamaoncol.2015.5570 PMID: 26794729","journal-title":"AMA Oncol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15) 01037-5","volume":"387(10024)","author":"James, N.D.","year":"2016","unstructured":"James, N.D.; Sydes, M.R.; Clarke, N.W.; Mason, M.D.; Dearnaley, D.P.; Spears, M.R.; Ritchie, A.W.; Parker, C.C.; Russell, J.M.; At-tard,G.; de Bono,J.; Cross,W.; Jones, R.J.; Thalmann,G.; Amos,C.; Matheson,D.; Millman,R.; Alzouebi,M.; Beesley,S.; Birtle, A.J.; Brock,S.; Cathomas,R.; Chakraborti,P.; Chowdhury,S.; Cook,A.; Elliott,T.; Gale,J.; Gibbs,S.; Graham, J.D.; Hethering-ton,J.; Hughes,R.; Laing,R.; McKinna,F.; McLaren, D.B.; O\u2019Sullivan, J.M.; Parikh,O.; Peedell,C.; Protheroe,A.; Robinson, A.J.; Srihari,N.; Srinivasan,R.; Staffurth,J.; Sundar,S.; Tolan,S.; Tsang,D.; Wagstaff,J.; Parmar, M.K. STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform random-ised controlled trial. Lancet. 2016,387(10024),1163-1177. http:\/\/dx.doi.org\/10.1016\/S0140-6736(15) 01037-5 PMID: 26719232","journal-title":"Lancet"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","volume":"32(11)","author":"Smith, M.R.","year":"2014","unstructured":"Smith, M.R.; Halabi,S.; Ryan, C.J.; Hussain,A.; Vogelzang,N.; Stadler,W.; Hauke, R.J.; Monk, J.P.; Saylor,P.; Bhoopalam,N.; Saad,F.; Sanford,B.; Kelly, W.K.; Morris,M.; Small, E.J. Ran-domized controlled trial of early zoledronic acid in men with cas-tration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (a lliance) . J. Clin. Oncol. 2014,32(11),1143-1150. http:\/\/dx.doi.org\/10.1200\/JCO.2013.51.6500 PMID: 24590644","journal-title":"J.Clin.Oncol"},{"key":"ref=25","first-page":"3837","volume":"33(9)","author":"Ueno,S.","year":"2013","unstructured":"Ueno,S.; Mizokami,A.; Fukagai,T.; Fujimoto,N.; Oh-Oka,H.; Kondo,Y.; Arai,G.; Ide,H.; Ho-rie,S.; Ueki,O.; Kawaguchi,K.; Shimamura,M.; Orito,M.; Ishida,T.; Ik eda,D.; Namiki, M. Effi-cacy of combined androgen blockade with zoledronic acid treat-ment in prostate cancer with bone metastasis: the ZABTON-PC (Zoledronic Acid\/Androgen Blockade Trial on Prostate Cancer)  study. Anticancer Res. 2013,33(9),3837-3844. PMID: 24023317","journal-title":"Anticancer Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","volume":"76(5)","author":"Saad,F.","year":"2010","unstructured":"Saad,F.; Eastham, J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with pros-tate cancer. Urology. 2010,76(5),1175-1181. http:\/\/dx.doi.org\/10.1016\/j.urology.2010.05.026 PMID: 21056263","journal-title":"Urology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","volume":"5(6)","author":"Saad,F.","year":"2007","unstructured":"Saad,F.; Chen, Y.M.; Gleason, D.M.; Chin, J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin. Genitourin. Cancer. 2007,5(6),390-396. http:\/\/dx.doi.org\/10.3816\/CGC.2007.n.022 PMID: 17956712","journal-title":"Clin.Genitourin.Cancer"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","volume":"4(1)","author":"Saad,F","year":"2005","unstructured":"Saad.; F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin. Prostate Cancer. 2005,4(1),31-37. http:\/\/dx.doi.org\/10.3816\/CGC.2005.n.009 PMID: 15992459","journal-title":"Clin.Prostate Cancer"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96(11)","author":"Saad,F.","year":"2004","unstructured":"Saad,F.; Gleason, D.M.; Murray,R.; Tchekmedyian,S.; Venner,P.; Lacombe,L.; Chin, J.L.; Vinholes, J.J.; Goas, J.A.; Zheng, M. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J. Natl. Cancer Inst. 2004,96(11),879-882. http:\/\/dx.doi.org\/10.1093\/jnci\/djh141 PMID: 15173273","journal-title":"J.Natl.Cancer Inst"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94(19)","author":"Saad,F.","year":"2002","unstructured":"Saad,F.; Gleason, D.M.; Murray,R.; Tchekmedyian,S.; Venner,P.; Lacombe,L.; Chin, J.L.; Vinholes, J.J.; Goas, J.A.; Chen, B. Zoledronic Acid Prostate Cancer Study Group. A randomized, pla-cebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J. Natl. Cancer Inst. 2002,94(19),1458-1468. http:\/\/dx.doi.org\/10.1093\/jnci\/94.19.1458 PMID: 12359855","journal-title":"J.Natl.Cancer Inst"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334(8)","author":"Berenson, J.R.","year":"1996","unstructured":"Berenson, J.R.; Lichtenstein,A.; Porter,L.; Dimopoulos, M.A.; Bordoni,R.; George,S.; Lipton,A.; Keller,A.; Ballester,O.; Kovacs, M.J.; Blacklock, H.A.; Be-ll,R.; Simeone,J.; Reitsma, D.J.; Heffernan,M.; Seaman,J.; Knight, R.D. Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma, N. Engl, J. Med. 1996,334(8),488-493. http:\/\/dx.doi.org\/10.1056\/NEJM199602223340802 PMID: 8559201","journal-title":"N.Engl, J.Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO","volume":"16(2)","author":"Berenson, J.R.","year":"1998","unstructured":"Berenson, J.R.; Lichtenstein,A.; Porter,L.; Dimopoulos, M.A.; Bordoni,R.; George,S.; Lipton,A.; Keller,A.; Ballester,O.; Kovacs,M.; Blacklock,H.; Be-ll,R.; Simeone, J.F.; Reitsma, D.J.; Heffernan,M.; Seaman,J.; Knight, R.D. Myeloma Aredia Study Group. Long-term pamidronate treatment of advanced mu ltiple myeloma patients reduces skeletal events, J. Clin. Oncol. 1998,16(2),593-602. http:\/\/dx.doi.org\/10.1200\/JCO. 1998.16.2.593 PMID: 9469347","journal-title":"J.Clin.Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335(24)","author":"Hortobagyi, G.N.","year":"1996","unstructured":"Hortobagyi, G.N.; Theriault, R.L.; Porter,L.; Blayney,D.; Lipton,A.; Sinoff,C.; Wheeler,H.; Simeone, J.F.; Seaman,J.; Knight, R.D. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group, N. Engl, J. Med. 1996,335(24),1785-1791. http:\/\/dx.doi.org\/10.1056\/NEJM199612123352401 PMID: 8965890","journal-title":"N.Engl, J.Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16(6)","author":"Hortobagyi, G.N.","year":"1998","unstructured":"Hortobagyi, G.N.; Theriault, R.L.; Lipton,A.; Porter,L.; Blayney,D.; Sinoff,C.; Wheeler,H.; Simeone, J.F.; Seaman, J.J.; Knight, R.D.; Heffernan,M.; Mellars,K.; Reitsma, D.J. Long-term preven-tion of skeletal complications of metastatic breast cancer with pa-midronate. Protocol 19 Aredia Breast Cancer Study Group, J. Clin. Oncol. 1998,16(6),2038-2044. http:\/\/dx.doi.org\/10.1200\/JCO.1998.16.6.2038 PMID: 9626201","journal-title":"J.Clin.Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)","volume":"88(5)","author":"Lipton,A.","year":"2000","unstructured":"Lipton,A.; Theriault, R.L.; Hortobagyi, G.N.; Simeone,J.; Knight, R.D.; Mellars,K.; Reitsma, D.J.; Heffernan,M.; Seaman, J.J. Pa-midronate prevents skeletal complications and is effective pallia-tive treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000,88(5),1082-1090. http:\/\/dx.doi.org\/10.1002\/(SICI). 1097-","journal-title":"Cancer"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17(3)","author":"Theriault, R.L.","year":"1999","unstructured":"Theriault, R.L.; Lipton,A.; Hortobagyi, G.N.; Leff,R.; Gl\u00fcck,S.; Stewart, J.F.; Costello,S.; Kennedy,I.; Simeone,J.; Seaman, J.J.; Knight, R.D.; Mellars,K.; Heffernan,M.; Reitsma, D.J. Pamidro-nate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group, J. Clin. On-col. 1999,17(3),846-854. http:\/\/dx.doi.org\/10.1200\/JCO.1999.17.3.846 PMID: 10071275","journal-title":"J.Clin.On-col"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","volume":"34(5)","author":"Winter, M.C.","year":"2008","unstructured":"Winter, M.C.; Holen,I.; Coleman, R.E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev. 2008,34(5),453-475. http:\/\/dx.doi.org\/10.1016\/j.ctrv.2008.02.004 PMID: 18423992","journal-title":"Cancer Treat.Rev"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.ejca.2009.04.022","volume":"45(11)","author":"Coleman,R.E","year":"2009","unstructured":"Coleman.; R.E. Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy? Eur, J. Cancer. 2009,45(11),1909-1915. http:\/\/dx.doi.org\/10.1016\/j.ejca.2009.04.022 PMID: 19447606","journal-title":"Cancer"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1677\/erc.0.0110207","volume":"11(2)","author":"Brown, J.E.","year":"2004","unstructured":"Brown, J.E.; Neville-Webbe,H.; Coleman, R.E. The role of bisphosphonates in breast and prostate cancers. Endocr. Relat. Cancer. 2004,11(2),207-224. http:\/\/dx.doi.org\/10.1677\/erc.0.0110207 PMID: 15163299","journal-title":"Endocr.Relat.Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10) 62344-6","volume":"377(9768)","author":"Fizazi,K.","year":"2011","unstructured":"Fizazi,K.; Carducci,M.; Smith,M.; Dami\u00e3o,R.; Brown,J.; Karsh,L.; Milecki,P.; Shore,N.; Rader,M.; Wang,H.; Jiang,Q.; Tadros,S.; Dansey,R.; Goessl, C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant pros-tate cancer: a randomised, double-blind study. Lancet. 2011,377(9768),813-822. http:\/\/dx.doi.org\/10.1016\/S0140-6736(10) 62344-6 PMID: 21353695","journal-title":"Lancet"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.juro.2012.11.016","volume":"189(1) (Suppl.)","author":"Smith, M.R.","year":"2013","unstructured":"Smith, M.R.; Morton, R.A.; Barnette, K.G.; Sieber, P.R.; Malk-owicz, S.B.; Rodriguez,D.; Hancock, M.L.; Steiner, M.S. Toremifene to reduce fracture risk in men receiving androgen dep-rivation therapy for prostate cancer, J. Urol. 2013,189(1) (Suppl.),S45-S50. http:\/\/dx.doi.org\/10.1016\/j.juro.2012.11.016 PMID: 23234631","journal-title":"Urol"},{"journal-title":"Semin..Oncol","author":"Bolger, J.J.","key":"ref=42","unstructured":"Bolger, J.J.; Dearnaley, D.P.; Kirk,D.; Lewington, V.J.; Mason, M.D.; Quilty, P.M.; Reed, N.S.; Russell, J.M.; Yardley, J. UK Me-tastron Investigators Group. Strontium-89 (Metastron)  versus ex-ternal beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: Preliminary report of a multicenter trial. Semin. Oncol. 1993,20(3) (Suppl. 2),32-33. PMID: 7684863"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.28103","volume":"119(17)","author":"Autio, K.A.","year":"2013","unstructured":"Autio, K.A.; Pandit-Taskar,N.; Carrasquillo, J.A.; Stephenson, R.D.; Slovin, S.F.; Rathkopf, D.E.; Hong,C.; Heller,G.; Scher, H.I.; Larson, S.M.; Morris, M.J. Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castra-tion-resistant prostate cancer. Cancer. 2013,119(17),3186-3194. http:\/\/dx.doi.org\/10.1002\/cncr.28103 PMID: 23765638","journal-title":"Cancer"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369(3)","author":"Parker,C.","year":"2013","unstructured":"Parker,C.; Nilsson,S.; Heinrich,D.; Helle, S.I.; O\u2019Sullivan, J.M.; Foss\u00e5, S.D.; Chodacki,A.; Wiechno,P.; Logue,J.; Seke,M.; Widmark,A.; Johannessen, D.C.; Hoskin,P.; Bottomley,D.; James, N.D.; Solberg,A.; Syndikus,I.; Kliment,J.; Wedel,S.; Boehmer,S.; Dall\u2019Oglio,M.; Franz\u00e9n,L.; Coleman,R.; Vogel-zang, N.J.; O\u2019Bryan-Tear, C.G.; Staudacher,K.; Garcia-Vargas,J.; Shan,M.; Bruland, \u00d8.S.; Sartor, O. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate can-cer, N. Engl, J. Med. 2013,369(3),213-223. http:\/\/dx.doi.org\/10.1056\/NEJMoa1213755 PMID: 23863050","journal-title":"N.Engl, J.Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bju.14015","volume":"121(1)","author":"Poon,Y.","year":"2018","unstructured":"Poon,Y.; Pechlivanoglou,P.; Alibhai, S.M.H.; Naimark,D.; Hoch, J.S.; Papadimitropoulos,E.; Hogan, M.E.; Krahn, M. Systematic review and network meta-analysis on the relative efficacy of osteo-porotic medications: Men with prostate cancer on continuous an-drogen-deprivation therapy to reduce risk of frag ility fractures. BJU Int. 2018,121(1),17-28. http:\/\/dx.doi.org\/10.1111\/bju.14015 PMID: 28921820","journal-title":"BJU Int"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","volume":"15(7)","author":"DePuy,V.","year":"2007","unstructured":"DePuy,V.; Anstrom, K.J.; Castel, L.D.; Schulman, K.A.; Weinfurt, K.P.; Saad, F. Effects of skeletal morbidities on longitudinal pa-tient-reported outcomes and survival in patients with metastatic prostate cancer. Support. Care Cancer. 2007,15(7),869-876. http:\/\/dx.doi.org\/10.1007\/s00520-006-0203-x PMID: 17262196","journal-title":"Support.Care Cancer"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/02841860510029617","volume":"44(6)","author":"Ull\u00e9n,A.","year":"2005","unstructured":"Ull\u00e9n,A.; Lennartsson,L.; Harmenberg,U.; Hjelm-Eriksson,M.; K\u00e4lkner, K.M.; Lennern\u00e4s,B.; Nilsson, S. Additive\/synergistic an-titumoral effects on prostate cancer cells in vitro following treat-ment with a combination of docetaxel and zoledronic acid. Acta Oncol. 2005,44(6),644-650. http:\/\/dx.doi.org\/10.1080\/02841860510029617 PMID: 16165924","journal-title":"Acta Oncol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15) 00489-1","volume":"17(2)","author":"Vale, C.L.","year":"2016","unstructured":"Vale, C.L.; Burdett,S.; Rydzewska, L.H.M.; Albiges,L.; Clarke, N.W.; Fisher,D.; Fizazi,K.; Gravis,G.; James, N.D.; Mason, M.D.; Parmar, M.K.B.; Sweeney, C.J.; Sydes, M.R.; Tombal,B.; Tierney, J.F. STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metas-tatic, hormone-sensitive prostate cancer: A systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016,17(2),243-256. http:\/\/dx.doi.org\/10.1016\/S1470-2045(15) 00489-1 PMID: 26718929","journal-title":"Lancet Oncol"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/182187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T19:32:46Z","timestamp":1602358366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/182187\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":47,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,9,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620666200521114815","relation":{},"ISSN":["1871-5206"],"issn-type":[{"type":"print","value":"1871-5206"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}